Bloods Before Drugs: The MRCP Drug Monitoring Guide
Every MRCP sitting, a predictable family of questions appears: which blood test, how often, and what do you do when it goes wrong? Drug monitoring is one of the highest-yield, lowest-effort areas of the entire syllabus — yet candidates routinely lose these marks because they learn the indications for drugs but never learn the housekeeping around them. This guide turns drug monitoring from a guessing game into guaranteed marks across MRCP Part 1, Part 2 and PACES.
Why Monitoring Questions Are Free Marks
Drug safety and monitoring questions appear in every paper:
Part 1 tests baseline investigations (e.g. TPMT before azathioprine), toxic thresholds and pharmacokinetic principles (phenytoin's zero-order kinetics).
Part 2 loves the scenario twist: a stable patient on methotrexate develops a cough, a patient on lithium starts naproxen, a heart failure patient is started on spironolactone — what is the single best next action?
PACES examiners expect safe prescribing conversations in Stations 2 and 5, and anticipatory care discussions in acute settings.
If you can recite the monitoring schedules below, you bank points in all three.
The Four Rules That Solve Most Monitoring Questions
Baseline before the first dose. TPMT (azathioprine), IGRA/chest X-ray (anti-TNF), retinal OCT (hydroxychloroquine), INR/FBC/U&E/LFT (anticoagulants).
Respect the early danger window. U&E at 1–2 weeks after starting an ACE inhibitor; FBC weekly for 18 weeks on clozapine; U&E at 1 week on spironolactone.
A new interacting drug means recheck. NSAID added to lithium, amiodarone added to warfarin, allopurinol added to azathioprine (never do it).
Symptoms plus drug = stop first, investigate second. Methotrexate pneumonitis, clozapine myocarditis and neutropenia, amiodarone thyrotoxicosis — the exam answer is almost always stop the drug.
The Big Six You Cannot Get Wrong
1. Methotrexate
Bloods: FBC, LFTs, U&E.
Schedule (BSR): every 2–4 weeks for the first 3 months, every 8–12 weeks for months 3–6, then every 12 weeks long term.
Exam pearls: prescribe folic acid at least 5 mg weekly (not on the same day); dry cough + dyspnoea = stop the drug and think pneumonitis; hold during significant infection; teratogenic in both sexes — stop at least 3 months before conception. Once weekly dosing only — fatal errors have occurred with daily dosing.
2. Lithium
Levels: 12 hours post-dose; weekly after initiation or dose change until stable, then every 3 months (NICE).
Bloods: U&E and TFTs every 6 months; calcium and weight periodically.
Toxicity: >1.5 mmol/L stop. Coarse tremor, vomiting, diarrhoea, cerebellar signs, confusion.
Interactions that scream exam question: NSAIDs, ACE inhibitors, ARBs, thiazides (reduce lithium clearance); SSRIs and verapamil add toxicity risk.
3. Clozapine
The 18–2–1 rule: FBC weekly for 18 weeks, then every 2 weeks until 1 year, then monthly for life.
Stop if neutrophils <1.5 ×10⁹/L (benign ethnic neutropenia uses adjusted ranges).
Early extras: myocarditis and pericarditis in the first 2 months (troponin if chest pain/flu-like illness), severe constipation, seizure threshold lowering, hypersalivation.
4. Amiodarone
Remember TLC: Thyroid function and Liver function every 6 months; annual Chest X-ray (plus ECG and ophthalmology review).
Baseline: TFTs, LFTs, U&E, ECG, CXR before starting.
Exam pearls: causes both hypo- and hyperthyroidism; pneumonitis; photosensitivity; slate-grey discolouration; corneal microdeposits; massively potentiates warfarin and digoxin.
5. ACE Inhibitors, ARBs and MRA
ACEi/ARB: U&E 1–2 weeks after starting and after each dose increase; watch for hyperkalaemia, rising creatinine (small rise acceptable), cough, angio-oedema. Never combine ACEi with ARB.
Spironolactone in HFrEF: U&E at 1 week, 1 month, then every 6 months; gynaecomastia — switch to eplerenone if it occurs.
6. Digoxin
Target in heart failure: 0.5–0.9 mcg/L; toxicity usually above 2 mcg/L.
Toxicity is potentiated by hypokalaemia, hypomagnesaemia, renal impairment, amiodarone, verapamil and macrolides.
Clinical picture: nausea, anorexia, confusion, xanthopsia (yellow vision), almost any arrhythmia (classically AV block with increased automaticity).
Specialty Monitoring Tables
Rheumatology and Immunosuppression
| Drug | Monitoring | Exam pearl |
|---|---|---|
| Methotrexate | FBC, LFT, U&E; 2–4 weekly ×3 months, then 3-monthly | Pneumonitis = stop; weekly dosing only |
| Sulfasalazine | FBC, LFT; 2–4 weekly ×3 months, then 3-monthly | Reversible oligospermia; orange discolouration |
| Leflunomide | FBC, LFT, BP, weight; as above | Long half-life; cholestyramine washout before pregnancy |
| Hydroxychloroquine | Retinal OCT baseline; annual screening after 5 years | Screen earlier if >5 mg/kg, eGFR <30, tamoxifen use |
| Azathioprine | TPMT first; then FBC, LFT | Never co-prescribe allopurinol |
| Anti-TNF | Exclude TB (IGRA/CXR), hepatitis B/C, HIV | Treat latent TB before starting |
| Rituximab | Immunoglobulins before and during | Risk of hypogammaglobulinaemia |
Psychiatry and Neurology
| Drug | Monitoring | Exam pearl |
|---|---|---|
| Lithium | Level 3-monthly; U&E/TFT 6-monthly | NSAIDs and ACEi push levels up |
| Clozapine | 18–2–1 FBC schedule | Neutrophils <1.5 = stop |
| Sodium valproate | LFTs, weight, FBC | Neural tube defects; pregnancy prevention programme |
| Carbamazepine | FBC, LFT, sodium | Hyponatraemia; HLA-B*1502 (SJS); enzyme inducer — OCP fails |
| Phenytoin | Level 10–20 mg/L | Zero-order kinetics — small dose change, big level change |
| Vigabatrin | Visual fields 6-monthly | Irreversible visual field constriction |
| Antipsychotics / methadone | ECG (QTc) | Additive with macrolides and antiemetics |
Cardiology and Anticoagulation
| Drug | Monitoring | Exam pearl |
|---|---|---|
| Amiodarone | TFT/LFT 6-monthly, annual CXR | Thyroid, liver, lungs, eyes, skin |
| Warfarin | INR 2–3 (2.5–3.5 for mechanical valve with risk factors) | Amiodarone and antibiotics potentiate |
| DOACs | FBC, U&E (±LFT) at least annually | Apixaban 2.5 mg BD if 2 of: age ≥80, weight ≤60 kg, creatinine ≥133 |
| Statins | Baseline LFT; CK only if myalgia | Routine repeated LFTs not required if baseline normal |
| Diuretics | U&E with intercurrent illness | Hyponatraemia with thiazides; hypokalaemia with loops |
Anti-infectives
| Drug | Monitoring | Exam pearl |
|---|---|---|
| Gentamicin | Pre-dose (trough) and post-dose levels | Ototoxicity, nephrotoxicity; synergy with furosemide = worse |
| Vancomycin | Trough 10–15 mg/L (15–20 in severe infection) | Red man reaction is rate-related, not allergic |
| Linezolid | Weekly FBC | Thrombocytopenia with >2 weeks use; serotonin syndrome with SSRIs |
| Anti-TB therapy | Baseline LFTs (RCP); repeat if risk factors | Give pyridoxine with isoniazid; ethambutol = colour vision; rifampicin = inducer |
Endocrine, Metabolic and Bone
| Drug | Monitoring | Exam pearl |
|---|---|---|
| Metformin | B12 if long-term use with anaemia/neuropathy; eGFR review | Stop if eGFR <30; hold in AKI |
| SGLT2 inhibitors | Renal function review; pause in acute illness, major surgery, prolonged fasting | Euglycaemic DKA; genital mycotic infections; Fournier gangrene |
| Isotretinoin | Lipids and LFTs at baseline and 1–2 months | Strict pregnancy prevention |
| Bisphosphonates | Correct calcium/vitamin D first; dental assessment | Osteonecrosis of the jaw; atypical femoral fractures |
| Denosumab | Calcium and vitamin D before each cycle; never significantly delay doses | Rebound vertebral fractures after stopping |
| Corticosteroids (long-term) | BP, glucose/HbA1c, DEXA, growth in children | Adrenal suppression; steroid card |
| Allopurinol | Renal function — start low, titrate to target urate | HLA-B*5801 (South-East Asian ancestry) — fatal SJS risk |
Sick-Day Rules: The Medications to Pause
When a patient develops a dehydrating illness (vomiting, diarrhoea, sepsis), advise pausing the AKI-associated medications:
NSAIDs
ACE inhibitors and ARBs
Diuretics (especially loop + thiazide combinations)
Metformin
SGLT2 inhibitors (pause during acute serious illness and perioperatively, but do not discontinue long term — their HF/CKD benefits persist)
Also exam favourites: hold methotrexate during significant infection, and never add an NSAID to lithium without checking levels.
QT Prolongation: The ECG Trap
Before starting QT-prolonging drugs — especially in older patients or those on multiple agents — an ECG is the safe answer. The classic list:
Antiarrhythmics: amiodarone, sotalol
Antibiotics: macrolides, fluoroquinolones
Antipsychotics: haloperidol, droperidol
Antidepressants: citalopram (dose-capped in the elderly)
Antiemeics: domperidone, ondansetron
Others: methadone, antimalarials, some antihistamines
If a Part 2 question shows syncope on multiple QT-drugs, think torsades and check the ECG first.
Test Yourself: Three Practice Questions
1. A 66-year-old man with HFrEF (EF 30%) on ramipril, bisoprolol and furosemide is started on spironolactone 25 mg daily. What is the most appropriate blood monitoring?
Answer: U&E at 1 week, again at 1 month, then every 6 months — hyperkalaemia and renal impairment cluster early.
2. A 28-year-old woman is planned to start azathioprine for autoimmune hepatitis. Which test must precede initiation?
Answer: TPMT (thiopurine methyltransferase) activity — low activity predicts profound myelosuppression.
3. A patient with bipolar disorder stable on lithium develops a coarse tremor, vomiting and ataxia two weeks after starting naproxen for back pain. Lithium level 1.9 mmol/L. What is the mechanism?
Answer: NSAIDs reduce renal prostaglandin-mediated lithium excretion, causing toxicity. Management: stop both drugs, IV fluids, urgent psychiatric review.
Memory Hooks That Stick
Clozapine: 18–2–1 (weeks → fortnights → monthly, forever)
Lithium: 3 and 6 (levels every 3 months, U&E/TFTs every 6 months)
Amiodarone: TLC — Thyroid, Liver, Chest X-ray
Methotrexate: 2–4–8–12 — the weekly rhythm of monitoring for life
Digoxin: under one in heart failure (0.5–0.9 mcg/L)
Spironolactone: 1 week, 1 month, 6 months
Hydroxychloroquine: screen at 5 (annual eyes after 5 years)
Anti-TNF: TB before TNF
Azathioprine: TPMT first
The 48-Hour Sweep Before Your Exam
Day 1 morning: rewrite the Big Six from memory; recite the rheumatology table.
Day 1 afternoon: psychiatry/neurology and cardiology tables; list every lithium interaction you can.
Day 2 morning: anti-infectives, endocrine and bone tables; sick-day rules; QT list.
Day 2 afternoon: 50 pharmacology questions from your question bank, focusing on monitoring and toxicity stems.
Sources worth quoting in PACES discussions: NICE CG185 (lithium), NICE CG178 (clozapine), BSR methotrexate safety guidelines, RCOphth hydroxychloroquine screening, RCP anti-tuberculosis therapy monitoring, and NICE heart failure guidance for MRA monitoring.
Final Thoughts
Drug monitoring questions reward preparation, not inspiration. The examiner is testing whether you will be a safe prescriber, not just a knowledgeable one. Learn the Big Six cold, skim the tables the night before, and walk into the exam knowing that when a stable patient on a monitored drug suddenly deteriorates, the answer is usually staring at you from this page: stop the drug, check the bloods, and explain to the patient why.
Join the Discussion
Share your thoughts and insights with the medical community
Comments
Delete Comment
Are you sure you want to delete this comment? This action cannot be undone.